Fenwick Represents Day One Biopharmaceuticals in Oversubscribed $175M Private Placement

Fenwick represented Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, in its oversubscribed $175 million private placement of common stock and pre-funded warrants. The private placement includes participation from both new and existing investors, as well as large investment management firms and several healthcare dedicated funds.

Day One intends to use the proceeds from the private placement, together with its existing cash, cash equivalents and short-term investments, to fund investment in its commercial capabilities, continued research and development activities, potential strategic acquisitions or licensing of complementary businesses or technologies, working capital and other general corporate purposes. More information can be obtained from the news announcement.

The Fenwick transaction team included corporate partners Effie Toshav, Rob Freedman and Julia Forbess and associates Arielle Trapp, Meg Moloney, Ankeet Ball, Susan Lee and Kosha Patel.